IPAC2019 - List of Authors (Abergel, R.J.)

Paper	Title	Page
THPMP051	Development of 211-Astatine Production in the Crocker Nuclear Laboratory Cyclotron	3564
	E. Prebys Fermilab, Batavia, Illinois, USA R.J. Abergel UCB, Berkeley, California, USA W.H. Casey University of California at Davis (UC Davis), Davis, California, USA D.A. Cebra UCD, Davis, California, USA
	There is a great deal of interest in the medical community in the use of the alpha-emitter 211-At as a therapeutic isotope. Among other things, its 7.2 hour half life is long enough to allow for recovery and labeling, but short enough to avoid long term activity in patients. Unfortunately, the only practical technique for its production is to bombard a 209-Bi target with a ~29 MeV alpha beam, so it is not accessible to commercial isotope production facilities, which all use fixed energy proton beams. The US Department of Energy is therefore supporting the development of a "University Isotope Network" (UIN) to satisfy this need. Our prposoal is to retrofit the variable-energy, multi-species cyclotron at the Crocker Nuclear Laboratory at the University of California Davis with an internal Bi-209 target, such that we can put at least 100 uA of 29 MeV alpha particles on target without concerns about extraction efficiency. Using very conservative assumptions, we are confident we will be able to produce 60 mCi of 211-At in solution in an eight hour shift, which includes setup, exposure, and chemical recovery. This poster will cover the design of the target, as well as the required chemical processing and reliability upgrades.
DOI •	reference for this paper ※ https://doi.org/10.18429/JACoW-IPAC2019-THPMP051
About •	paper received ※ 15 May 2019 paper accepted ※ 22 May 2019 issue date ※ 21 June 2019
Export •	reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)

Paper

Title

Page

Development of 211-Astatine Production in the Crocker Nuclear Laboratory Cyclotron

3564

E. Prebys
Fermilab, Batavia, Illinois, USA
R.J. Abergel
UCB, Berkeley, California, USA
W.H. Casey
University of California at Davis (UC Davis), Davis, California, USA
D.A. Cebra
UCD, Davis, California, USA

There is a great deal of interest in the medical community in the use of the alpha-emitter 211-At as a therapeutic isotope. Among other things, its 7.2 hour half life is long enough to allow for recovery and labeling, but short enough to avoid long term activity in patients. Unfortunately, the only practical technique for its production is to bombard a 209-Bi target with a ~29 MeV alpha beam, so it is not accessible to commercial isotope production facilities, which all use fixed energy proton beams. The US Department of Energy is therefore supporting the development of a "University Isotope Network" (UIN) to satisfy this need. Our prposoal is to retrofit the variable-energy, multi-species cyclotron at the Crocker Nuclear Laboratory at the University of California Davis with an internal Bi-209 target, such that we can put at least 100 uA of 29 MeV alpha particles on target without concerns about extraction efficiency. Using very conservative assumptions, we are confident we will be able to produce 60 mCi of 211-At in solution in an eight hour shift, which includes setup, exposure, and chemical recovery. This poster will cover the design of the target, as well as the required chemical processing and reliability upgrades.

DOI •

reference for this paper ※ https://doi.org/10.18429/JACoW-IPAC2019-THPMP051

About •

paper received ※ 15 May 2019 paper accepted ※ 22 May 2019 issue date ※ 21 June 2019

Export •

reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)